Loading...

High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas

BACKGROUND: Immunotherapy has demonstrated encouraging clinical benefits in patients with advanced breast carcinomas and Programmed death ligand 1 (PD-L1) expression has been proposed as an immunotherapy biomarker. Challenges with current PD-L1 testing exist and tumor mutation burden (TMB) is emergi...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Diagn Pathol
Main Authors: Mei, Ping, Freitag, C. Eric, Wei, Lai, Zhang, Yunxiang, Parwani, Anil V., Li, Zaibo
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2020
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7212599/
https://ncbi.nlm.nih.gov/pubmed/32393302
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13000-020-00971-7
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!